Abstract
Extended survival of liver transplant recipients has brought rejection management to the forefront of liver transplant research. This article discusses T-cell–mediated rejection, antibody-mediated rejection, and chronic rejection. We focus on the prevention and then discuss treatment options. Future directions of rejection management include biomarkers of rejection, which may allow for monitoring of patients who are considered high risk for rejection and detection of rejection before there is any clinical evidence to improve graft and patient survival. With improved graft life and survival of liver transplant recipients, the new frontier of rejection management focuses on immunosuppression minimization, withdrawal, and personalization.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 53-72 |
| Number of pages | 20 |
| Journal | Clinics in liver disease |
| Volume | 25 |
| Issue number | 1 |
| DOIs | |
| State | Published - Feb 2021 |
Funding
Dr J. Levitsky is a consultant, stockholder, and recipient of research funds from Viracor, Eurofins, and Transplant Genomics Inc.; Dr J. Levitsky is a consultant, speaker, and recipient of research funds from Novartis. Dr C.R. Harrington and Dr G-Y. Yang have nothing to disclose.
Keywords
- Antibody-mediated rejection
- Biomarkers of rejection
- Immunosuppression minimization
- T-cell mediated rejection
- Tolerance
ASJC Scopus subject areas
- Hepatology